In the latest trading session, 3.1 million BioXcel Therapeutics Inc (NASDAQ:BTAI) shares changed hands as the company’s beta touched 0.60. With the company’s most recent per share price at $2.46 changing hands around $0.26 or 11.81% at last look, the market valuation stands at $8.09M. BTAI’s current price is a discount, trading about -1915.45% off its 52-week high of $49.58. The share price had its 52-week low at $1.72, which suggests the last value was 30.08% up since then. When we look at BioXcel Therapeutics Inc’s average trading volume, we note the 10-day average is 1.77 million shares, with the 3-month average coming to 4.70 million.
Analysts gave the BioXcel Therapeutics Inc (BTAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.75. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended BTAI as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. BioXcel Therapeutics Inc’s EPS for the current quarter is expected to be -5.14.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI is in green as seen in intraday trades today. With action 1.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -58.88%, with the 5-day performance at 1.23% in the green. However, in the 30-day time frame, BioXcel Therapeutics Inc (NASDAQ:BTAI) is 8.36% up. Looking at the short shares, we see there were 0.33 million shares sold at short interest cover period of 0.07 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need a downside of -146.0% from its recent market value. According to analyst projections, BTAI’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a 59.35% surge from its current level, while the stock would need to tank 59.35% for it to hit the projected low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Year-over-year growth is forecast to reach 106.09% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 718.26k. 2 analysts are of the opinion that BioXcel Therapeutics Inc’s revenue for the current quarter will be 350k. The company’s revenue for the corresponding quarters a year ago was 376k and 582k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 91.03%. The estimates for the next quarter sales put growth at -39.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.97%. The 2025 estimates are for BioXcel Therapeutics Inc earnings to increase by 74.58%, but the outlook for the next 5-year period is at 50.34% per year.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15.38% of BioXcel Therapeutics Inc shares while 14.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 16.62%. There are 14.06% institutions holding the BioXcel Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 3.1438% of the shares, roughly 0.97 million BTAI shares worth $1.24 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.4276% or 0.44 million shares worth $0.56 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 55.39 shares estimated at $0.13 million under it, the former controlled 1.73% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.57% of the shares, roughly 18.33 shares worth around $43843.0.
